Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cardiol Therapeutics Inc
T.CRDL
Alternate Symbol(s):
CRDL
Healthcare
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is...
recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CRDL)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(25)
•••
BeyondValuez
X
View Profile
View Bullboard History
Post by
BeyondValuez
on Oct 09, 2024 9:10am
New Issue Priced at $1.60 USD
Whats with Canaccord? They have sever work to do so this can get going. Was told $10 million institutional. Their deals suck as of late.
(6)
•••
rowdyrhino
X
View Profile
View Bullboard History
Post by
rowdyrhino
on Aug 21, 2024 2:20pm
Write-up on Cardiol from MicroCap Opportunities
Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease https://open.substack.com/pub/microcapopportunities/p/cspi-a-spinoff-is-hopefully-developing?utm_campaign=post&utm
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 27, 2024 12:30pm
New Press Release - Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of...
read article.
(208)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 25, 2024 2:00pm
Cardiol Therapeutics to Webcast Virtual Annual General and S
News; $CRDL Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDTToronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 25, 2024 7:28am
New Press Release - Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of...
read article.
(10)
•••
Royal10
X
View Profile
View Bullboard History
Post by
Royal10
on Jun 24, 2024 10:29am
Strong breakouts: CRDL and WELL
CRDL: new Cannacord price target: $8.00 and WELL: TD tgt= $8.00!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 17, 2024 7:00am
New Press Release - Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
(NewsDirect)In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study topline results. The Canadian biotechnology company has...
read article.
(33)
•••
Hideaway
X
View Profile
View Bullboard History
Post by
Hideaway
on Jun 13, 2024 4:36pm
Whacked!
I've seen junior biotechs get hit on news but this seems extreme to be off 85 cents on a pretty positive NR.Hope it is only a one day affair. Tomorrow should provide some indication. May take a
...more
(66)
•••
Alim33
X
View Profile
View Bullboard History
Post by
Alim33
on Jun 13, 2024 8:26am
Great positive news out!
This explains the big jump in the last few days. Now, is it sell on news? I certainly hope that this is not the case. GLTA.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 13, 2024 7:59am
New Press Release - Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 11, 2024 6:00am
New Press Release - Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
(NewsDirect)Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of treatments for...
read article.
(66)
•••
Alim33
X
View Profile
View Bullboard History
Post by
Alim33
on Jun 10, 2024 1:29pm
New 52 week high! $3.84, up more than 15%
Hope not too much profit taking near the end of the day! Don't ruin the momentum!
(66)
•••
Alim33
X
View Profile
View Bullboard History
Comment by
Alim33
on Jun 09, 2024 3:09pm
RE:This one is a real gem!
Sorry, I jinxed this with my posting and started a pull back. Hopefully, it is over and we'll start moving again.
(66)
•••
Alim33
X
View Profile
View Bullboard History
Comment by
Alim33
on Jun 07, 2024 2:08pm
RE:I think we have finally reached the bottom
Sorry, wrong place!
(66)
•••
Alim33
X
View Profile
View Bullboard History
Post by
Alim33
on Jun 07, 2024 2:08pm
I think we have finally reached the bottom
Around $1.25 is probably the bottom before the next leg up. GLTA.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Major Funding Secured! Company Closes First Round of Private Placement
This $10M Deal Could Reshape the Future of Global Creator Platforms
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits